{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+2&page=28", "query": { "intervention": "Level 2", "page": 28 }, "page_size": 10 }, "pagination": { "page": 28, "page_size": 10, "total_count": 7721, "total_pages": 773, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+2&page=29&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+2&page=27&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T18:11:50.716Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05372354", "title": "A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "CC-92480", "type": "DRUG" }, { "name": "Tazemetostat", "type": "DRUG" }, { "name": "BMS-986158", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2022-10-18", "completion_date": "2026-10-12", "has_results": false, "last_update_posted_date": "2025-09-05", "last_synced_at": "2026-10-23T18:11:50.716Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05372354" }, { "nct_id": "NCT05850494", "title": "Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "HFA MDI", "type": "DRUG" }, { "name": "HFO MDI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 52, "start_date": "2023-05-02", "completion_date": "2023-08-21", "has_results": true, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-10-23T18:11:50.716Z", "location_count": 4, "location_summary": "North Dartmouth, Massachusetts • St Louis, Missouri • Raleigh, North Carolina + 1 more", "locations": [ { "city": "North Dartmouth", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "El Paso", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05850494" }, { "nct_id": "NCT00671931", "title": "Susceptibility of Motor-Evoked Potentials to Varying Targeted Blood Levels of Dexmedetomidine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Scoliosis" ], "interventions": [ { "name": "low dexmedetomidine, low propofol", "type": "DRUG" }, { "name": "high dexmedetomidine, low propofol", "type": "DRUG" }, { "name": "Dexmedetomidine", "type": "DRUG" }, { "name": "Dexmedetomidin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "10 Years to 25 Years" }, "enrollment_count": 44, "start_date": "2007-04", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2013-08-23", "last_synced_at": "2026-10-23T18:11:50.716Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671931" }, { "nct_id": "NCT01390402", "title": "Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "NK cell infusion:", "type": "PROCEDURE" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Anti-Thymocyte Globulin", "type": "DRUG" }, { "name": "Allogeneic related Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 6, "start_date": "2012-01", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2016-02-03", "last_synced_at": "2026-10-23T18:11:50.716Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01390402" }, { "nct_id": "NCT04592380", "title": "Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dyspnea", "Hypertension", "Acute Heart Failure" ], "interventions": [ { "name": "Stage 1: Clevidipine (double-blinded)", "type": "DRUG" }, { "name": "Stage 1: Placebo (double-blinded)", "type": "DRUG" }, { "name": "Stage 2: Clevidipine (open-label)", "type": "DRUG" }, { "name": "Stage 2: Standard of Care (open-label)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Medicines Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-08", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-10-23T18:11:50.716Z", "location_count": 9, "location_summary": "Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Brooklyn", "state": "New York" }, { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04592380" }, { "nct_id": "NCT04019327", "title": "A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Prostate Adenocarcinoma", "Prostate Neoplasm", "Prostate Cancer Metastatic", "Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Talazoparib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 16, "start_date": "2019-07-11", "completion_date": "2025-12-04", "has_results": true, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-23T18:11:50.716Z", "location_count": 9, "location_summary": "Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 6 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04019327" }, { "nct_id": "NCT02630303", "title": "High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fibrosis", "Scarring", "Scar", "Wounds", "Injuries", "Keloid", "Cicatrix", "Hypertrophic" ], "interventions": [ { "name": "LED-RL Phototherapy", "type": "DEVICE" }, { "name": "Mock Therapy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Jared Jagdeo, MD, MS", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 60, "start_date": "2016-01", "completion_date": "2017-03", "has_results": false, "last_update_posted_date": "2017-03-31", "last_synced_at": "2026-10-23T18:11:50.716Z", "location_count": 1, "location_summary": "Mather, California", "locations": [ { "city": "Mather", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02630303" }, { "nct_id": "NCT05019651", "title": "Acceptability and Feasibility of Apollo in Veterans With a History of PTSD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "PTSD" ], "interventions": [ { "name": "Apollo Wearable System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Lisa Brenner", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 63, "start_date": "2022-02-01", "completion_date": "2023-06-30", "has_results": false, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-10-23T18:11:50.716Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05019651" }, { "nct_id": "NCT01539291", "title": "Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2012-10-03", "completion_date": "2018-06-29", "has_results": true, "last_update_posted_date": "2019-08-20", "last_synced_at": "2026-10-23T18:11:50.716Z", "location_count": 30, "location_summary": "Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 24 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01539291" }, { "nct_id": "NCT00891462", "title": "Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Aclidinium bromide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 561, "start_date": "2009-04", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2017-01-06", "last_synced_at": "2026-10-23T18:11:50.716Z", "location_count": 104, "location_summary": "Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00891462" } ] }